CNBX
CNBX Pharmaceuticals Inc.
Next earnings Jul 13, 2026
$0.00
▲ +100.00%$0.00▼ -77.78%
over 1Y
L $0.00H $0.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+100.0%
1W+0.0%
1M+0.0%
3M+100.0%
YTD-50.0%
1Y-77.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity -0.20x); but revenue fell -100.0% YoY.
Revenue (FY2025) $0.00 · FY2025
CNBX Pharmaceuticals Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and 12.6% ROE.
Supporting the case: conservative balance sheet (liabilities/equity -0.20x).
Is CNBX a buy? The one-page verdict, explained →
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $30.0K | $410K | $130K | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$2.60M | -$2.95M | -$931K | -$583K | -$272K |
| Net income | -$3.19M | -$3.72M | -$3.71M | -$695K | -$314K |
| Diluted EPS | -$0.02 | -$3.59 | -$0.42 | -$0.02 | $0.00 |
| Net margin | — | -12428.2% | -904.6% | -534.5% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$226K
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-130.4%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$15.1K
Altman Z-Score-2129.55 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1680.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-05-312026-06-24open ↗SCHEDULE 13G/AFiling2026-05-08open ↗10-QPeriod ending 2026-02-282026-04-14open ↗8-KPeriod ending 2026-03-102026-03-17open ↗SCHEDULE 13G/AFiling2026-02-05open ↗10-QPeriod ending 2025-11-302026-01-14open ↗10-KPeriod ending 2025-08-312025-12-01open ↗SCHEDULE 13G/AFiling2025-11-10open ↗SCHEDULE 13G/AFiling2025-08-13open ↗10-QPeriod ending 2025-05-312025-07-14open ↗SCHEDULE 13G/AFiling2025-05-13open ↗10-QPeriod ending 2025-02-282025-04-14open ↗
Frequently asked
- Is CNBX Pharmaceuticals Inc. (CNBX) a buy?
- CNBX currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -0.20x); but revenue fell -100.0% YoY.
- What is CNBX Pharmaceuticals Inc.'s quality score?
- CNBX scores 55.090909090909086/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001343009, latest 10-Q filed 2026-06-24) · EODHD · as of 6/22/2026, 11:36:39 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 22, 2026, 7:36 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.